BDBM622523 US20230312583, Compound V-1

SMILES CCOc1cc(Nc2ncc3ccc4ncn(CC)c4c3n2)ncc1N1CCN(CC)CC1

InChI Key InChIKey=JFYAFMMSOVKSEU-UHFFFAOYSA-N

Data  5 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 5 hits for monomerid = 622523   

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622523(US20230312583, Compound V-1)
Affinity DataIC50: 0.175nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622523(US20230312583, Compound V-1)
Affinity DataIC50: 1.44nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetMast/stem cell growth factor receptor Kit(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622523(US20230312583, Compound V-1)
Affinity DataIC50: 21.3nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622523(US20230312583, Compound V-1)
Affinity DataIC50: 221nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622523(US20230312583, Compound V-1)
Affinity DataIC50: 298nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent